In part one of this two-part series, Dr. Dan Ackerman and Dr. Trey Bateman discuss current biomarkers for Alzheimer disease and how do you use them in clinic.

Dr. Justin Abbatemarco discusses updates around MOGAD treatments.

Show references:

https://jamanetwork.com/journals/jamaneurology/article-abstract/2822964

https://jnnp.bmj.com/content/95/11/1054

Dr. Justin Abbatemarco discusses autoimmune encephalitis with a focus on outcomes.

Show references:

https://www.neurology.org/doi/10.1212/WNL.0000000000210109

https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00463-5/abstract

Dr. Halley Alexander discusses the Neurology Today article, “The AAN Updates Its Position Statement on Seizures, Driver Licensure, and Medical Reporting,” by Gina Shaw, available in the latest issue of Neurology Today or at neurologytoday.com.

Show reference:

The AAN Updates Its Position Statement on Seizures, Driver Licensure, and Medical Reporting

Dr. Greg Cooper and Dr. Joseph Therriault discuss the use of plasma biomarkers in diagnosing Alzheimer disease.

Show reference:

https://doi.org/10.1038/s43587-024-00731-y

Dr. Halley Alexander and Dr. Paula Marques discuss sex differences in genetically determined epilepsies.

Show reference:

https://www.neurology.org/doi/10.1212/NXG.0000000000200233

Dr. Justin Abbatemarco discusses updates around treatments in AQP4+ NMOSD.

Show references:

https://pubmed.ncbi.nlm.nih.gov/38760098/

https://www.neurology.org/doi/10.1212/NXI.0000000000200071

In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss how to address questions related to BTK Inhibitors with patients.

Show reference:

https://www.nejm.org/doi/full/10.1056/NEJMoa2415985

https://www.nejm.org/doi/full/10.1056/NEJMoa2415988